ADVM Adverum Biotechnologies Inc.

3.59
-0.07  -2%
Previous Close 3.66
Open 3.65
Price To Book 1.05
Market Cap 225697481
Shares 62,868,379
Volume 388,557
Short Ratio
Av. Daily Volume 725,825

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 181188940
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170674
  3. 8-K - Current report 181136543
  4. 8-K - Current report 181126610
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001705

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Development to be discontinued - noted November 1, 2018.
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
AVA-101
Wet age-related macular degeneration (Wet-AMD)
Phase 1 trial initiation announced November 19, 2018. Interim data due 1Q 2020.
ADVM-022
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. What Bargains? Play 5 Stocks With Rising P/E Instead
  2. Is Adverum Biotechnologies, Inc. (ADVM) A Good Stock To Buy?
  3. Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
  4. Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
  5. Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
  6. Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
  7. Adverum Biotechnologies: 3Q Earnings Snapshot
  8. Adverum Biotechnologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  9. Investor Expectations to Drive Momentum within Consolidated Edison, MUELLER WATER PRODUCTS, Adverum Biotechnologies, Buckeye Partners, inTest, and Live Nation Entertainment — Discovering Underlying Factors of Influence
  10. Adverum Biotechnologies (ADVM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  11. Here's Why Adverum Biotechnologies Dropped as Much as 42.4% Today
  12. Apple, Cirrus Logic, GoPro, and More: Here’s Why These Stocks Are On the Move
  13. The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug
  14. Adverum Biotechnologies Provides Program Updates
  15. The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs
  16. Adverum Biotechnologies Announces Appointment of Leone Patterson as CEO and Member of the Board of Directors
  17. Adverum Biotechnologies Announces Data Presented at the European Society of Gene and Cell Therapy (ESGCT)
  18. Consolidated Research: 2018 Summary Expectations for Mimecast, Shiloh Industries, Adverum Biotechnologies, AngioDynamics, Kimball Electronics, and Changyou — Fundamental Analysis, Key Performance Indications
  19. Cantor Fitzgerald's 7 Buys For 7 Biotechs